Indoleamine 2,3-Dioxygenase: Expressing Cells in Inflammatory Bowel Disease—A Cross-Sectional Study

Table 1

Demographic and clinical characteristics of Crohn’s disease and ulcerative colitis patients.

Variable	Healthy donors; (𝑛=10)	Active CD patients; (𝑛=6)	Inactive CD patients; (𝑛=8)	Active UC patients; (𝑛=10)	Inactive UC patients; (𝑛=10)
Age, years
Mean ± SD	40.3±6.7	45.0±18.4	40.0±9.3	44.7±14.9	41.5±14.9
Median	40.0	44.0	42.0	46.0	43.0
Range	29–51	22–67	25–52	20–69	20–70
Sex, female/male	4/6	1/5	1/7	3/7	5/5
Disease duration, years
<3		0%	25%	0%	10%
>3		100%	75%	100%	90%
Treatment
Mesalazine		5/6	0/8	10/10	10/10
Azathioprine		1/6	2/8	7/10	3/10
Prednisone		4/6	0/8	9/10	1/10
Mercaptopurine		1/6	1/8	0/10	0/10
Disease extension
Distal colitis		0/6	8/8	3/10	7/10
Pancolitis		6/6	0/8	7/10	3/10
Extraintestinal manifestations
Absent		6/6	8/8	8/10	7/10
Present		0/6	0/8	2/10	3/10

CD: Crohn’s disease patient group; UC: ulcerative colitis patient group.